Clinical Trial: Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)

U.S., May 28 -- ClinicalTrials.gov registry received information related to the study (NCT07608432) titled 'Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)' on May 20.

Brief Summary: The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.

Study Start Date: June, 2026

Study Type: INTERVENTIONAL

Condition: Duchenne Muscular Dystrophy (DMD) Muscular Dystrophy, Duche...